Vaccine breakthrough SARS-CoV-2 infection has been monitored in 3720 healthcare workers receiving 2 doses of BNT162b2. SARS-CoV-2 infection is detected in 33 subjects, with a 100-day cumulative incidence of 0.93%. Vaccine protection against acquisition of SARS-CoV-2 infection is 83% (95%CI: 58–93%) in the overall population and 93% (95%CI: 69-99%) in SARS-CoV-2-experienced subjects, when compared with a non-vaccinated control group from the same Institution, in which SARS-CoV-2 infection occurs in 20/346 subjects (100-day cumulative incidence: 5.78%). The infection is symptomatic in 16 (48%) vaccinated subjects vs 17 (85%) controls (p = 0.01). All analyzed patients, in whom the amount of viral RNA was sufficient for genome sequencing, results infected by the alpha variant. Antibody and T-cell responses are not reduced in subjects with breakthrough infection. Evidence of virus transmission, determined by contact tracing, is observed in two (6.1%) cases. This real-world data support the protective effect of BNT162b2 vaccine. A triple antigenic exposure, such as two-dose vaccine schedule in experienced subjects, may confer a higher protection. Several COVID-19 vaccines have shown good efficacy in clinical trials. Here, the authors provide real world effectiveness data in a group of BNT162b2 vaccinated health care workers and find that breakthrough infections are asymptomatic or mild.
【저자키워드】 SARS-CoV-2, Translational research, RNA vaccines, 【초록키워드】 Efficacy, Vaccine, BNT162b2 vaccine, COVID-19 vaccine, Health care, antibody, SARS-COV-2 infection, health care workers, T-cell Response, variant, Infection, clinical trials, Contact tracing, virus transmission, real-world data, healthcare worker, BNT162b2, Genome sequencing, Viral, Asymptomatic, symptomatic, Effectiveness, Control, Health care worker, Mild, Alpha, breakthrough infections, Viral RNA, Breakthrough infection, Alpha variant, incidence, patients, T-cell responses, protective effect, dose, evidence of, determined by, Support, control group, subject, institution, antigenic, cumulative, acquisition, shown, analyzed, receiving, reduced, subjects, occur, of BNT162b2, 【제목키워드】 variant, SARS-CoV-2 vaccine, Asymptomatic, symptomatic, Health care worker,